Regeneron Pharmaceuticals (REGN) Announces Earnings Results
Regeneron Pharmaceuticals (NASDAQ:REGN) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05, Bloomberg Earnings reports. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.04 earnings per share.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded down $7.13 during trading on Friday, reaching $315.49. 847,068 shares of the company were exchanged, compared to its average volume of 979,870. The company has a market capitalization of $35,950.16, a P/E ratio of 28.73, a price-to-earnings-growth ratio of 1.26 and a beta of 1.47. Regeneron Pharmaceuticals has a 12 month low of $314.99 and a 12 month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.
Hedge funds have recently made changes to their positions in the business. Arizona State Retirement System boosted its stake in shares of Regeneron Pharmaceuticals by 2.7% in the fourth quarter. Arizona State Retirement System now owns 19,518 shares of the biopharmaceutical company’s stock valued at $7,338,000 after buying an additional 518 shares during the period. Trexquant Investment LP bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $3,863,000. First Allied Advisory Services Inc. lifted its stake in Regeneron Pharmaceuticals by 19.1% during the fourth quarter. First Allied Advisory Services Inc. now owns 2,208 shares of the biopharmaceutical company’s stock worth $835,000 after purchasing an additional 354 shares during the last quarter. Advisory Services Network LLC lifted its stake in Regeneron Pharmaceuticals by 147.0% during the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares during the last quarter. Finally, Global X Management Co. LLC lifted its stake in Regeneron Pharmaceuticals by 81.2% during the fourth quarter. Global X Management Co. LLC now owns 2,417 shares of the biopharmaceutical company’s stock worth $909,000 after purchasing an additional 1,083 shares during the last quarter. 65.69% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2018/02/08/regeneron-pharmaceuticals-regn-releases-earnings-results-beats-estimates-by-0-71-eps.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.